AZD 0865

Drug Profile

AZD 0865

Alternative Names: AR-H044277; AZD 865; AZD0865; Front-loaded

Latest Information Update: 10 Aug 2005

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiulcers
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 28 Jul 2005 Discontinued - Phase-II for Gastro-oesophageal reflux in Europe (PO)
  • 31 May 2005 Data presented at the Digestive Disease Week-2005 (DDW-2005) have been added to the adverse events, pharmacokinetics and Peptic Ulcer Disease pharmacodynamics sections ,
  • 12 Jan 2005 A preclinical study has been added to the Peptic Ulcer Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top